Clinical Trial Update: Adiponectin in Patients With Metabolic Disorders [NA]

View source ↗

Summary

A clinical trial evaluating adiponectin in patients with metabolic disorders including MAFLD and type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Fatty Liver Disease
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Moscow Regional Research and Clinical Institute (MONIKI) | Conditions: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM) | NA | Status: COMPLETED